(VIANEWS) - Equus Total Return (EQS), Surgery Partners (SGRY), Ares Commercial Real Estate Corporation (ACRE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Equus Total Return (EQS)
139.2% sales growth and 9.4% return on equity
Equus Total Reward, Inc., a business development firm (BDC), specializes in management buyouts, leveraged buyouts and recapitalizations. It also offers equity and equity-oriented securities from privately held companies. This includes debt securities, including subordinate debt and debt that can be converted into common stock or preferred stock. It acts as an investor lead and invests in companies from small to medium size. The fund invests in alternative energy, real-estate, healthcare, education and e-learning. It also supports foreign investments in Europe, the United States and China. Common and preferred stock are all investments. The debt can be converted into preferred stock or common stock. There is also debt that comes with options and warrants. Other rights include the right to purchase common stock or preferred stock. This fund invests in businesses with annual revenues of between $10 and $100 million. Equus Total Reward, Inc. was established in Houston Texas in 1991. It also has a Vancouver office.
Equus Total Return's sales growth this year is expected to be 139.2% and 24.9% for next year.
Year-on-year quarterly revenue growth declined by 0%, now sitting on N/A for the twelve trailing months.
Volume
Today's last reported volume for Equus Total Return is 505 which is 96.04% below its average volume of 12753.
Equus Total Return's sales growth for the next quarter is 139.2%. The company's growth estimates for the ongoing quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.4%.
Volatility
Equus Total Return's last day, last week, and last month's current intraday variation average was 0.97%, 1.29%, and 2.23%, respectively.
Equus Total Return's highest amplitude of average volatility was 0.98% (day), 1.50% (last week), and 2.15% (last month), respectively.
Equus Total Return's Stock Yearly Top and Bottom Value
Equus Total Return's stock is valued at $2.06 at 06:22 EST, way below its 52-week high of $2.73 and higher than its 52-week low of $1.96.
Equus Total Return's Moving Average
Equus Total Return's worth is below its 50-day moving average of $2.27 and way below its 200-day moving average of $2.42.2. Surgery Partners (SGRY)
13.7% sales growth and 5.17% return on equity
Surgery Partners, Inc., via its subsidiaries, operates and owns a network in America of surgical facilities as well as ancillary services. Two segments of the company are Surgical Facility Service and Ancillary. The company's surgical centers include ambulatory surgical centers as well as surgical hospitals which offer non-emergency surgery in various specialties such as gastroenterology and general surgery. A number of ancillary services are offered by the company's medical hospitals, including diagnostic imaging, pharmacy and laboratory, obstetrics and oncology and physical therapy. It owned or managed 126 operating surgical centers, which included 108 ambulatory surgery centers, and 18 hospitals across 31 states. Surgery Partners, Inc. was established in 2004 in Brentwood, Tennessee.
Surgery Partners's sales growth this year is expected to be 14.3% and 11.6% for next year.
Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 2.38B for the twelve trailing months.
Volume
Today's last reported volume for Surgery Partners is 15148 which is 97.06% below its average volume of 515296.
Surgery Partners's sales growth for the next quarter is 13.7%. The company's growth estimates for the present quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.17%.
Volatility
Surgery Partners's last day, last week, and last month's current intraday variation average was 1.70%, 2.95%, and 3.38%, respectively.
Surgery Partners's highest amplitude of average volatility was 2.10% (day), 3.78% (last week), and 5.65% (last month), respectively.
Surgery Partners's Stock Yearly Top and Bottom Value
Surgery Partners's stock is valued at $34.33 at 06:23 EST, way below its 52-week high of $63.87 and way above its 52-week low of $26.66.
Surgery Partners's Moving Average
Surgery Partners's worth is higher than its 50-day moving average of $33.64 and way under its 200-day moving average of $45.05.3. Ares Commercial Real Estate Corporation (ACRE)
12.8% sales growth and 7.28% return on equity
Ares Commercial Real Estate Corporation is a special finance firm that invests in and originates commercial real estate loans in the United States. The company offers a variety of financing options for CRE property owners and operators. It originates subordinate and senior mortgage products as well as mezzanine, mezzanine, and other CRE investment, such commercial mortgage-backed securities, mortgage-backed securities, mortgage preferred equity investments, mortgage preferred equity investments, mortgage preferred equity investments, and real estate prefered debt products. Ares Commercial Real Estate Corporation is qualified and has chosen to be taxed under the Internal Revenue Code of 1986 as a real property investment trust. As the manager, Ares Commercial Real Estate Management LLC manages the company. It was established in New York in 2011.
Ares Commercial Real Estate Corporation's sales growth this year is expected to be 19.4% and 13% for next year.
Year-on-year quarterly revenue growth declined by 35.6%, now sitting on 90.66M for the twelve trailing months.
Volume
Today's last reported volume for Ares Commercial Real Estate Corporation is 44026 which is 93.33% below its average volume of 660437.
Ares Commercial Real Estate Corporation's sales growth is a negative 0% for the present quarter and 12.8% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 5.4% and negative -9.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.28%.
Volatility
Ares Commercial Real Estate Corporation's last day, last week, and last month's current intraday variation average was 0.97%, 1.15%, and 1.24%, respectively.
Ares Commercial Real Estate Corporation's highest amplitude of average volatility was 1.56% (day), 1.49% (last week), and 1.96% (last month), respectively.
Ares Commercial Real Estate Corporation's Stock Yearly Top and Bottom Value
Ares Commercial Real Estate Corporation's stock is valued at $13.60 at 06:23 EST, way below its 52-week high of $16.48 and way above its 52-week low of $11.18.
Ares Commercial Real Estate Corporation's Moving Average
Ares Commercial Real Estate Corporation's worth is above its 50-day moving average of $12.92 and below its 200-day moving average of $14.43.4. Zoetis (ZTS)
8% sales growth and 47.76% return on equity
Zoetis Inc. develops, produces, markets, and sells diagnostic and animal medicine products, vaccines and other health products both in the United States as well as internationally. The company sells products across all species. This includes livestock such as sheep, cattle, chickens, turkeys, fish and poultry; companion animals including dogs, cats and horses. It also sells vaccines. These are biological preparations designed to prevent disease in the respiratory, digestive, and reproductive tracts. Other pharmaceutical products include antiemetic and reproductive products, pain and sedation products, dermatology products to treat allergic conditions, and medications for livestock. The company also offers portable urine and blood analysis, which includes instruments and reagents for point-of care diagnostics. It can also provide reference kits, laboratory kits, blood glucose monitors, blood glucose monitoring, blood sugar monitors, and rapid immunoassay testing. The company markets its products directly to livestock producers and veterinarians. It also sells its products through third-party distributors. It was established in Parsippany in New Jersey in 1952.
Zoetis's sales growth this year is expected to be 15.1% and 8.3% for next year.
Year-on-year quarterly revenue growth grew by 11.4%, now sitting on 7.62B for the twelve trailing months.
Volume
Today's last reported volume for Zoetis is 1290590 which is 21.7% below its average volume of 1648310.
Zoetis's sales growth is a negative 0% for the ongoing quarter and 8% for the next. The company's growth estimates for the present quarter and the next is 0.9% and 11%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 47.76%.
Volatility
Zoetis's last day, last week, and last month's current intraday variation average was 0.35%, 0.41%, and 1.44%, respectively.
Zoetis's highest amplitude of average volatility was 2.05% (day), 1.74% (last week), and 1.97% (last month), respectively.
Zoetis's Stock Yearly Top and Bottom Value
Zoetis's stock is valued at $156.91 at 06:24 EST, way under its 52-week high of $231.91 and way above its 52-week low of $141.41.